In Vivo CAR-T: Development Status and Implications for Cell-Therapy Capacity | Oncology Modality Intelligence

Description

List of Tables

CAR-T therapy works, and in Japan it works slowly. Every ex vivo product depends on a vein-to-vein chain - leukapheresis, shipment, manufacturing, release, return - that caps how many patients a certified center can treat, and Japan's certified-center network is small relative to its need. In vivo CAR-T proposes to delete that chain entirely: instead of engineering cells in a factory, deliver the engineering machinery to the patient and let the body manufacture its own CAR-T cells. In 2025 the idea stopped being theoretical. AstraZeneca acquired EsoBiotec in March, taking the ENaBL lentiviral platform and its BCMA program into first-in-human testing; AbbVie acquired Capstan Therapeutics in June for its CD8-targeted LNP approach; Gilead's Kite unit bought Interius BioTherapeutics in August; and Lilly swept up Orna and Kelonia in early 2026. The valuations attached to these deals rest on early human evidence, and the gap between platform promise and clinical proof is the central tension: which delivery technology - integrating lentivirus, transient LNP-mRNA, circular RNA - produces durable, controllable, safe cell engineering inside a patient, and which produces a brief pharmacologic effect dressed as a cell therapy? For Japan the implications run in both directions. If in vivo approaches deliver, they could relax the capacity constraint that has defined Japanese cell therapy, bypassing the apheresis-and-slot economy entirely; they would also reset the manufacturing question toward vectors and LNPs, an area where Japanese players such as Takara Bio hold relevant capability. Japan-specific development activity is not yet established, and this report says so plainly where the evidence base is thin. It maps the platforms and programs, the acquisition wave and its logic, the delivery-science trade-offs, the autoimmune expansion that may reach the clinic before oncology does, and the scenarios under which in vivo CAR-T reaches Japanese patients. It serves cell-therapy investors, cell-and-gene business-development teams, Japanese CDMOs, and hospital strategists planning the next decade of cellular medicine.

Scope and Coverage

The report covers in vivo CAR-T delivery platforms, the 2025-2026 acquisition wave, early clinical programs in oncology and autoimmunity, manufacturing and vector-supply considerations, and Japan's capacity-constraint context, explicitly flagging where Japan-specific development is unverified.

Report Highlights

Platform taxonomy: integrating lentivirus, targeted LNP-mRNA, and circular-RNA approaches
ESO-T01, CPTX2309, UB-VV111, and INT2104: the leading in vivo programs profiled
The acquisition wave: AstraZeneca/EsoBiotec, AbbVie/Capstan, Kite/Interius, Lilly/Orna and Kelonia
Why autoimmune indications may lead oncology to the clinic
Japan's ex vivo CAR-T capacity constraint and how in vivo approaches interact with it
Vector and LNP manufacturing implications, including Japanese CDMO relevance

Product Code: JPH-103

Table of Content

1. Executive Summary

2. In Vivo CAR-T: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

AstraZeneca (UK) - acquirer of EsoBiotec (Mar 2025); ESO-T01 BCMA in vivo CAR-T first-in-human program
EsoBiotec (BE) - ENaBL lentiviral in vivo cell-engineering platform behind ESO-T01
AbbVie (US) - acquirer of Capstan Therapeutics (Jun 2025); CPTX2309 CD19 targeted-LNP program in Phase 1 for autoimmune disease
Capstan Therapeutics (US) - CD8-targeted LNP-mRNA in vivo CAR platform, now an AbbVie subsidiary
Umoja Biopharma (US) - VivoVec lentiviral-LNP hybrid platform; UB-VV111 in Phase 1; AbbVie partnership (2023)
Gilead/Kite (US) - acquirer of Interius BioTherapeutics (Aug 2025); ex vivo CAR-T leader hedging into in vivo
Interius BioTherapeutics (US) - INT2104 CD20 in vivo CAR using an integrating vector without lymphodepletion
Eli Lilly (US) - acquirer of Orna (Feb 2026) and Kelonia (Apr 2026)
Orna Therapeutics (US) - circular RNA LNP in vivo CAR platform, now with Lilly
Kelonia Therapeutics (US) - in vivo gene-delivery platform for CAR generation, now with Lilly
Sana Biotechnology (US) - CD8-fusogen pseudotyped lentivirus in vivo platform
IASO Biotherapeutics (CN) - China cell-therapy company with in vivo CAR programs
JW Therapeutics (CN) - relma-cel commercial operator exploring in vivo approaches in China
Takara Bio (JP) - Japanese vector and CDMO capacity relevant to in vivo delivery manufacturing

Product Code: JPH-103

List of Tables

Table 1. Ex vivo CAR-T value chain and its capacity constraints in Japan
Table 2. In vivo CAR-T concept: delivery routes, payloads, and engineering logic
Table 3. Platform taxonomy: integrating vectors versus transient LNP-mRNA systems
Table 4. EsoBiotec ENaBL platform and the ESO-T01 BCMA program
Table 5. AstraZeneca acquisition of EsoBiotec (2025): structure and strategic logic
Table 6. Capstan CD8-targeted LNP platform and the CPTX2309 CD19 program
Table 7. AbbVie acquisition of Capstan (2025) and the autoimmune development plan
Table 8. Umoja VivoVec platform and the UB-VV111 program
Table 9. Umoja-AbbVie partnership (2023) in the in vivo field
Table 10. Interius INT2104: CD20-directed in vivo CAR without lymphodepletion
Table 11. Gilead/Kite acquisition of Interius (2025) as an ex vivo incumbent's hedge
Table 12. Orna circular-RNA LNP platform and the Lilly acquisition (2026)
Table 13. Kelonia in vivo gene-delivery platform and the Lilly acquisition (2026)
Table 14. Sana Biotechnology fusogen-pseudotyped lentivirus approach
Table 15. IASO Biotherapeutics in vivo programs in China
Table 16. JW Therapeutics exploration of in vivo approaches alongside relma-cel
Table 17. Target landscape for in vivo programs: BCMA, CD19, CD20, and CD8-directed delivery
Table 18. Lymphodepletion requirements across in vivo platforms
Table 19. Durability and redosing questions for transient-expression platforms
Table 20. Safety considerations: off-target transduction, cytokine events, and insertional risk
Table 21. Autoimmune indication expansion: lupus and related programs
Table 22. Oncology development logic for in vivo approaches in myeloma and lymphoma
Table 23. Early clinical evidence read across first-in-human programs
Table 24. Manufacturing implications: vector and LNP production requirements
Table 25. Takara Bio vector and CDMO capability relevant to in vivo delivery
Table 26. Japanese cell-therapy regulatory framework and its application to in vivo constructs
Table 27. Japan's certified-center network for ex vivo CAR-T: structure and throughput
Table 28. Referral and slot-allocation mechanics in Japanese CAR-T practice
Table 29. Bispecific antibody competition as an off-the-shelf comparator in Japan
Table 30. Deal-term benchmarks across the in vivo acquisition wave, 2025-2026
Table 31. Valuation frameworks for platform-stage in vivo companies
Table 32. Comparative analysis: in vivo versus ex vivo cost and logistics structures
Table 33. Comparative analysis: in vivo CAR-T versus bispecific antibodies
Table 34. Preclinical evidence standards expected by regulators for in vivo programs
Table 35. CMC and release-testing challenges for in vivo delivery products
Table 36. Scenario grid for in vivo CAR-T clinical validation by platform type
Table 37. Scenario grid for Japan adoption: capacity relief versus infrastructure displacement
Table 38. Competitive-position matrix of in vivo platforms and their owners
Table 39. Partnership archetypes linking in vivo platforms to established cell-therapy players
Table 40. Risk register for investors in platform-stage in vivo companies
Table 41. Risk register for ex vivo incumbents facing modality disruption
Table 42. Key opinion leader perspectives on in vivo approaches in hematology
Table 43. Regulatory-question checklist for first in vivo filings
Table 44. Watchlist of in vivo program milestones, 2026-2028
Table 45. China in vivo landscape and its interaction with global programs
Table 46. Stakeholder map: platform companies, acquirers, CDMOs, and treatment centers
Table 47. Technology-assessment framework for vector-versus-LNP delivery
Table 48. Historical analogies: modality transitions that reset manufacturing economics
Table 49. Implications for Japanese hospital and CDMO investment planning
Table 50. Timeline of in vivo CAR-T development and deal events, 2023-2026

List of Figures

Figure 1. Ex vivo CAR-T vein-to-vein chain and its constraint points
Figure 2. In vivo CAR-T concept schematic: engineering inside the patient
Figure 3. Delivery-platform taxonomy: lentivirus, LNP-mRNA, and circular RNA
Figure 4. ENaBL platform mechanism and the ESO-T01 program
Figure 5. AstraZeneca-EsoBiotec transaction map (2025)
Figure 6. Capstan targeted-LNP mechanism and CPTX2309 design
Figure 7. AbbVie-Capstan transaction map (2025)
Figure 8. Umoja VivoVec architecture and UB-VV111 program
Figure 9. Interius INT2104 design: integrating vector without lymphodepletion
Figure 10. Kite-Interius transaction as an incumbent hedge
Figure 11. Orna and Kelonia platforms under Lilly ownership (2026)
Figure 12. Sana fusogen-pseudotyping approach diagram
Figure 13. China in vivo landscape: IASO and JW Therapeutics
Figure 14. Target map for in vivo programs across BCMA, CD19, and CD20
Figure 15. Lymphodepletion requirement spectrum across platforms
Figure 16. Durability and redosing question map for transient platforms
Figure 17. Safety-consideration map for in vivo cell engineering
Figure 18. Autoimmune expansion path for in vivo programs
Figure 19. Oncology development path for in vivo programs
Figure 20. Early clinical evidence landscape across first-in-human studies
Figure 21. Vector and LNP manufacturing requirement map
Figure 22. Takara Bio capability position in in vivo delivery supply
Figure 23. Japan cell-therapy regulatory framework applied to in vivo constructs
Figure 24. Japan certified-center network map for ex vivo CAR-T
Figure 25. Referral and slot-allocation flow in Japanese CAR-T practice
Figure 26. Bispecific antibodies as the off-the-shelf comparator in Japan
Figure 27. In vivo acquisition-wave timeline, 2025-2026
Figure 28. Deal-term benchmark map across the acquisition wave
Figure 29. Platform-stage valuation framework schematic
Figure 30. Cost and logistics comparison: in vivo versus ex vivo
Figure 31. Modality comparison: in vivo CAR-T versus bispecific antibodies
Figure 32. Preclinical evidence standards for in vivo programs
Figure 33. CMC and release-testing challenge map
Figure 34. Clinical-validation scenario tree by platform type
Figure 35. Japan adoption scenario tree: capacity relief versus displacement
Figure 36. Competitive-position map of in vivo platforms
Figure 37. Partnership archetypes in the in vivo field
Figure 38. Risk map for platform-stage investors
Figure 39. Risk map for ex vivo incumbents
Figure 40. Hematology KOL perspective landscape on in vivo approaches
Figure 41. Regulatory-question checklist for first in vivo filings
Figure 42. In vivo milestone calendar, 2026-2028
Figure 43. China-global interaction map for in vivo programs
Figure 44. Stakeholder map across platforms, acquirers, CDMOs, and centers
Figure 45. Vector-versus-LNP technology-assessment framework
Figure 46. Modality-transition analogies from manufacturing history
Figure 47. Implications map for Japanese hospital investment planning
Figure 48. Key-question tree for cell-therapy investors
Figure 49. Key-question tree for CGT business development
Figure 50. In vivo CAR-T development and deal timeline, 2023-2026

In Vivo CAR-T: Development Status and Implications for Cell-Therapy Capacity | Oncology Modality Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. In Vivo CAR-T: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures